Chrysophanol: A promising natural compound in cancer therapy - Mechanistic insights and future perspectives

Dehong Liu1, Kun Zhu1, Tao Guo1

  • 1Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.

Pharmacological Research
|November 9, 2024
PubMed

Insights

Chrysophanol, a natural compound, shows promise in fighting cancer by controlling cell death and spread. Further research is needed to overcome challenges and confirm its effectiveness in clinical trials.

Area of Science:

  • Natural Products Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Cancer remains a major global health challenge, necessitating novel therapeutic approaches.
  • Chrysophanol, an anthraquinone, exhibits diverse biological activities with potential anti-cancer applications.

Purpose of the Study:

  • To review the anti-cancer mechanisms of chrysophanol.
  • To discuss its potential in inhibiting cancer progression and enhancing chemotherapy.
  • To identify challenges and future research directions for chrysophanol in cancer therapy.

Main Methods:

  • Literature review of studies on chrysophanol's anti-cancer effects.
  • Analysis of mechanisms including cell cycle arrest, apoptosis, autophagy, and necrosis.
  • Evaluation of its impact on invasion, metastasis, and drug sensitivity.

Main Results:

  • Chrysophanol induces cell cycle arrest, apoptosis, autophagy, and necrosis in various cancer cells.
  • It inhibits cancer cell invasion and metastasis.
  • Chrysophanol modulates chemotherapy sensitivity.

Conclusions:

  • Chrysophanol demonstrates significant anti-cancer potential through multiple mechanisms.
  • Challenges like poor solubility and bioavailability require further investigation.
  • Clinical trials are crucial to establish chrysophanol's efficacy and safety for cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K